ZK824190

ZK824190 is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively[1].

Product Specifications

CAS Number

[2254001-81-3]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

PAI-1; Ser/Thr Protease

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/zk824190.html

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

CC[C@@H](OC1=NC(OC2=CC(C3=CC=CC(CN)=C3)=CC=C2)=C(F)C=C1F)C(O)=O

Molecular Formula

C22H20F2N2O4

Molecular Weight

414.40

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28 (20) :3372-3375.